Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431041
Status:
COMPLETED
Last Update Posted:
2010-06-08
First Post:
2007-02-01
Brief Title:
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder VECTOR
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
VECTOR A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin Vesicare in Comparison to Oxybutynin for Overactive Bladder Patients
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VECTOR
Brief Summary:
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release IR for the treatment of overactive bladder OAB
Detailed Description:
This study is a prospective randomized double-blind double-dummy multicentre 2-arm 1 Active Active Control comparative parallel group study to compare the safety and efficacy of solifenacin with oxybutynin immediate-release IR for the treatment of overactive bladder OAB
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None